公开(公告)号：US20240342134A1

公开(公告)日：2024-10-17

申请号：US18682201

申请日：2022-08-09

Applicant: Mor Research Applications Ltd.

Inventor： Ohad S. Birk ,  Yuval Yogev

IPC: A61K31/366 ,  A61K9/00 ,  A61P21/00

CPC classification number: A61K31/366 ,  A61K9/0053 ,  A61P21/00

Abstract: The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to damaged or hindered HMG CoA-reductase enzyme. Oral administration of mevalonolactone is provided for treating muscle cell and/or tissue damage caused at least in part due to impaired mevalonic acid production, as effected in diseases and disorders such as myopathy, statin-associated muscle symptom (SAMS), immune-mediated necrotizing myopathy (IMNM), rhabdomyolysis, muscular toxicity syndrome, myalgia, sarcopenia, and limb girdle muscular dystrophy (LGMD).